Science-led immune health
T-Booster supportsimmune healthby enhancingthymus function
T-Booster combines an 18-ingredient formulation, drug-discovery experience and a randomised human study in a responsible programme for healthy immune ageing.
01 · Programme architecture
A scientific programme—not simply a product.
T-Booster brings together computational research, scientific review, formulation discipline, UK GMP manufacturing and controlled human evaluation.
Selected formulation
18
vitamins, minerals and nutraceuticals assessed for rationale, dose, safety and manufacturing suitability.
Computational starting point
Machine learning and computer modelling supported the early research process.
Scientific judgement
Evidence review and multidisciplinary input guided ingredient and dose selection.
Manufacturing route
A 66,000-capsule UK GMP batch supported study delivery and scale-up learning.
Controlled evaluation
A randomised, double-blind, placebo-controlled adult study assessed biological and participant-reported outcomes.
Biological focusThymus function and new T‑cell output
02 · Why the thymus matters
A small organ with a central role in immune development.
The thymus develops precursor cells into specialised T cells that support defence, immune memory and surveillance. Its activity naturally declines with age.
- 01
T-cell development
Immune precursor cells mature and learn to recognise biological threats while limiting inappropriate responses.
- 02
Healthy immune ageing
Age-related thymic decline reduces the output and diversity of newly formed T cells.
- 03
Measurable biological context
TREC DNA provides a marker of newly generated T cells and an indication of thymic output.
03 · Human clinical programme
A structured comparison between T-Booster and placebo.
Participant involvement is complete. Laboratory analysis, statistical interpretation and publication preparation continue.
The programme combines a molecular marker of newly generated T cells, wider blood analysis and an 18-question participant questionnaire.
Explore the clinical study04 · Evidence framework
Three layers build the scientific picture.
No single endpoint tells the whole story. Biological markers, wider laboratory measures and participant experience are considered together.
01
Molecular marker
TREC DNA
A marker of newly generated T cells and an indication of thymic output.
02
Laboratory context
CBC and lymphocytes
Blood measures provide wider context for immune-cell and safety findings.
03
Participant experience
Questionnaire outcomes
Responses covered energy, sleep, stress, pain, urinary health, mood, skin and sexual wellbeing.
Among participants who reported a specific concern at baseline, the chart shows the proportion of that subgroup who reported improvement at the four-month assessment.
What participants noticed in everyday life.
Questionnaires compared responses at programme entry and completion. Positive signals must be interpreted alongside the blinded placebo comparison, TREC DNA, complete blood count and final statistical analysis.
Baseline-defined subgroups
Four-month follow-up
Participant reported
Explore participant-reported outcomes →
06 · Programme film
The science, people and vision behind T-Booster.
The presentation introduces the thymus rationale, formulation journey and wider ambition for responsible consumer-health innovation.
Official presentation
The Future of Longevity
The power of thymus reactivation
07 · Scientific leadership
Drug-discovery experience guiding the programme.
Leadership combines structural biology, cancer science, pharmaceutical R&D, formulation development and commercial perspective.
01
Founder & CEO · PhD
Dr Md Arif Sheikh
Scientific architect of T-Booster, with 20 years of drug-discovery experience and contributions to more than 45 protein structures.
- Drug discovery
- Thymus research
- Structural biology
02
Scientific advisor · PhD, FRSM, FRSC
Dr David Brown
Pharmaceutical drug discoverer with more than 50 years of experience across major global companies and a co-inventor on the Viagra patent.
- Pharmaceutical R&D
- Drug discovery
- Medicinal chemistry
08 · Commercial pathway
From completed participation towards evidence-led market preparation.
Current work includes final analysis, reporting, intellectual property, production planning, distribution and launch preparation.
- 01Human participationComplete
- 02Laboratory and statistical analysisCurrent phase
- 03Publication and intellectual propertyCurrent phase
- 04Manufacturing and distributionMarket preparation
Frequently asked questions
Clear answers about status and intended use.
Updates will follow as scientific analysis, publication, intellectual-property activity and launch preparation continue.
Is T-Booster available to buy?
T-Booster is moving towards commercial launch. Contact the team for confirmed availability information.
Has the human study finished?
Participant involvement is complete. Laboratory analysis, statistical interpretation and publication are being finalised.
What is T-Booster intended to do?
It is positioned responsibly as a food supplement intended to support thymus function and healthy immune ageing.
Is this a medical treatment?
No. T-Booster is not intended to diagnose, treat, cure or prevent disease.